Terms: = Brain cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
4 results:
1. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
[TBL] [Abstract] [Full Text] [Related]
2. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
Opel D; Westhoff MA; Bender A; Braun V; Debatin KM; Fulda S
Cancer Res; 2008 Aug; 68(15):6271-80. PubMed ID: 18676851
[TBL] [Abstract] [Full Text] [Related]
3. Apoptotic markers for primary brain tumor prognosis.
Konstantinidou AE; Korkolopoulou P; Patsouris E
J Neurooncol; 2005 Apr; 72(2):151-6. PubMed ID: 15925995
[TBL] [Abstract] [Full Text] [Related]
4. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and cd95 (apo-1/fas) proteins are not prognostic factors in de novo glioblastoma multiforme.
Kraus JA; Wenghoefer M; Glesmann N; Mohr S; Beck M; Schmidt MC; Schröder R; Berweiler U; Roggendorf W; Diete S; Dietzmann K; Heuser K; Müller B; Fimmers R; von Deimling A; Schlegel U
J Neurooncol; 2001 May; 52(3):263-72. PubMed ID: 11519857
[TBL] [Abstract] [Full Text] [Related]
